Author:
McDonald Paul C.,Chafe Shawn C.,Brown Wells S.,Saberi Saeed,Swayampakula Mridula,Venkateswaran Geetha,Nemirovsky Oksana,Gillespie Jordan A.,Karasinska Joanna M.,Kalloger Steve E.,Supuran Claudiu T.,Schaeffer David F.,Bashashati Ali,Shah Sohrab P.,Topham James T.,Yapp Donald T.,Li Jinyang,Renouf Daniel J.,Stanger Ben Z.,Dedhar Shoukat
Funder
Canadian Cancer Society Research Institute
Canadian Institutes of Health Research
Pancreas Centre BC
BC Cancer Foundation
VGH Foundation
Subject
Gastroenterology,Hepatology
Reference32 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
2. Pancreatic cancer;Kleeff;Nat Rev Dis Primers,2016
3. Integrated genomic characterization of pancreatic ductal adenocarcinoma;Cancer Cell,2017
4. Metabolic dependencies in RAS-driven cancers;Kimmelman;Clin Cancer Res,2015
5. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas;Infante;Eur J Cancer,2014
Cited by
162 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献